Azitra advances ATR-04 trial to second cohort after safety review
Tweet Send to a Friend
Azitra, Inc. (NYSE American: AZTR) announced Oct. 1 that its Phase 1/2 clinical trial evaluating ATR04-484 has advanced to Cohort ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
